UBS Maintains a 'Neutral' on Seattle Genetics (SGEN); Strong Results in Hodgkin Lymphoma
Tweet Send to a Friend
UBS maintains a 'Neutral' on Seattle Genetics (Nasdaq: SGEN), raises PT from $12.50 to $14.50.
UBS analyst says, "SGEN, along ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "SGEN, along ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
